Every material Form 8-K ORAMED PHARMACEUTICALS INC. has filed with the SEC since February 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Oramed and Scilex Holding agreed on June 25, 2026 to a further extension of Scilex's payment obligations to Oramed under two senior notes. Scilex has paid $0.5 million so far, with $5 million due by July 31, 2026 and the remaining balance due by September 30, 2026. The filing also says Oramed's board approved amended bylaws effective June 25, 2026 that change stockholder written consent procedures.
Scilex owed approximately $29.5 million under the Tranche A Note and $6.7 million under the Tranche B Note as of June 30, 2026.
Oramed received $0.5 million from Scilex on June 25, 2026; $5 million is due on or before July 31, 2026, and the remaining balance on or before September 30, 2026.
If Scilex does not pay in full by September 30, 2026, the first $1.5 million received would be treated as a non-refundable extension fee, and Scilex has agreed to settle the remaining amount with Scilex common stock.
Fifth Amended and Restated Bylaws, effective June 25, 2026, revise record date procedures for written consent, eliminate a information requirement for record date requests, and set a 60-day delivery window for consents.
Oramed said Lifeward Ltd. completed its acquisition of Oratech Pharma, Oramed's wholly owned subsidiary, on March 25, 2026, paying with Lifeward shares, warrants and a revenue-based payment stream. The same day, Oramed closed a $9,000,000 purchase of Lifeward senior secured convertible notes, which the filing describes as previously announced terms being finalized rather than new terms.
Lifeward issued Oramed 1,250,363 ordinary shares, 1,006,113 pre-funded warrants at $0.0001 per share, and warrants for up to 1,296,296 shares at an initial $5.40 exercise price.
Oramed will receive revenue-based payments equal to 4% of Net Revenue from Lifeward's ReWalk Personal Exoskeleton products and related extended warranties, for up to 10 years or until earlier defined limits.
Oramed bought $9,000,000 aggregate principal of Lifeward notes, convertible at an initial $5.40 per share, plus warrants for up to 1,666,666 Lifeward shares.
Both transactions closed on March 25, 2026, under agreements dated January 12, 2026.
On February 19, 2026, Oramed entered a Warrant Agreement with Scilex Holding Company. Oramed deferred an amortization payment originally due October 1, 2025 on Scilex's Tranche B Notes, in exchange for a new warrant to buy 100,000 Scilex common shares at an initial exercise price of $20.00 per share. The deferred payment was made to Oramed in November 2025, and the warrant is immediately exercisable.
Warrant Agreement with Scilex dated February 19, 2026, with the warrant to buy 100,000 Scilex common shares at an initial $20.00 exercise price
Warrant expires December 13, 2029 and is immediately exercisable; the exercise price can adjust, with a floor of $8.22 per share
Deferred amortization payment originally scheduled for October 1, 2025 on the Tranche B Notes was paid in November 2025
Oramed may not exercise the warrant if that would give it more than 4.99% of Scilex's outstanding common stock, a limit it can raise to no more than 9.99%
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ORAMED PHARMACEUTICALS INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →